Source: http://www.google.com/patents/US5434081?dq=7143430
Timestamp: 2015-07-04 05:53:50
Document Index: 544259657

Matched Legal Cases: ['Application No. 70166', 'Application No. 134958', 'Application No. 20820', 'Application No. 70166', 'Application No. 134958', 'Application No. 282698', 'art.2']

Patent US5434081 - Method of classifying leukocytes by flow cytometry - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsA method for leukocyte classification by flow cytometry that uses a first fluid that is hypotonic acidic fluorescent dye solution and a second fluid that is a solution that changes the osmolarity and pH of the first fluid is disclosed. The first fluid to be used in the method incorporates not only the...http://www.google.com/patents/US5434081?utm_source=gb-gplus-sharePatent US5434081 - Method of classifying leukocytes by flow cytometryAdvanced Patent SearchPublication numberUS5434081 APublication typeGrantApplication numberUS 08/131,016Publication dateJul 18, 1995Filing dateOct 1, 1993Priority dateNov 16, 1990Fee statusLapsedAlso published asDE69120026D1, DE69120026T2, EP0485945A2, EP0485945A3, EP0485945B1Publication number08131016, 131016, US 5434081 A, US 5434081A, US-A-5434081, US5434081 A, US5434081AInventorsYasunori MaekawaOriginal AssigneeToa Medical ElectronicsExport CitationBiBTeX, EndNote, RefManPatent Citations (16), Non-Patent Citations (2), Referenced by (28), Classifications (18), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetMethod of classifying leukocytes by flow cytometry
US 5434081 AAbstract
A method for leukocyte classification by flow cytometry that uses a first fluid that is hypotonic acidic fluorescent dye solution and a second fluid that is a solution that changes the osmolarity and pH of the first fluid is disclosed. The first fluid to be used in the method incorporates not only the first and second dyes but also the third dye and this insures that even leukocytes with damaged cell membrane can be distributed as entities distinct from other leukocyte types on a two-dimensional plot. And, hence, high precision of leukocyte classification is assured even in the case of assaying blood that contains damaged cells as a result of prolonged standing at room temperature after sampling.
1. A method of classifying leukocytes by flow cytometry which comprises the steps of:(a) mixing a sample of blood with hypotonic first fluid comprising a first dye that is a fluorescent dye capable of selectively staining both eosinophils and basophils, said first dye being Astrazon Yellow 3G, a second dye that is a fluorescent dye capable of staining the nuclei of leukocytes, said second dye selected from the group consisting of: Acridine Red; Rhodamine S; Rhodamine 6G Rhodamine B Rhodamine 19 perchlorate; Rhodamine 123 Eosin Y; Cyanosine; Cresyl Fast Violet; Darrow Red; Acronol Phloxine FFS; 1,1'-dimethylthiocarbocyanine; 1,1'-diethylthiocarbocyanine; 1,1-diethyl-9-methylthiocarbocyanine bromide; 2-[γ-(1'-ethyl-4', 5'-benzothiazolylidene) -propenyl]-1-ethyl-4,5-benzoxazolium iodide; Astrazon Red 6B; Basic Violet 16; 2-(p-dimethylaminostyryl-1-ethyl-4,5 benzo-thiazolium iodide; 2,4-bis(p-dimethylaminostyryl)-1-ethyl-pyridinium iodide; 2,6-bis(p-dimethylaminostyryl)-1-ethyl-pyridinium iodide; and Astrazon Orange R;a third dye that is a fluorescent dye capable of staining the nuclei of leukocytes with damaged cell membrane, said third dye selected from the group consisting of Propidium Iodide, Etidium Bromide and M-264, and a buffer for maintaining a pH in an acidic range to obtain a first sample solution, incubating said first sample solution; (b) mixing the first sample solution obtained in step (a) with a second fluid comprising a buffer that neutralizes acid in the first fluid for maintaining the pH of the solution at a staining pH and an osmolarity adjusting agent for adjusting the osmolarity of the solution to a value at which the leukocytes remain unchanged in shape to obtain a second sample solution, incubating said second sample solution, said dyes cooperating to enable a combined total incubation period of about one minute; (c) loading the second sample solution obtained in step (b) in a flow cytometer and obtaining more than one signal for parameters including fluorescence and scattered light in association with individual types of leukocytes; (d) constructing a first two-dimensional plot of intensities of scattered light and green fluorescence from the signals as emitted from leukocytes, said plot containing distribution zones of each intact leukocyte type, and counting leukocytes within each zone to obtain a number for each leukocyte type located in the distribution zones of intact leukocytes; (e) further separating and counting leukocytes within distribution zones of individual leukocyte types on said first two-dimensional plot by determining distribution zones for leukocytes that deviate from the distribution zones of intact leukocytes where they would otherwise be located, (f) Constructing, for the leukocyte groups in those determined distribution zones that deviate from the distribution zones of intact leukocytes, a second two-dimensional plot of the intensities of scattered light and red fluorescence, (g) separating on said second two-dimensional plot those leukocytes that deviate and counting to obtain a number of such leukocytes in each zone; (h) combining the number of each leukocyte type located in the distribution zones of intact leukocytes and the number of leukocytes that deviate from said zones to obtain a total number of each type of leukocytes in said blood sample. 2. A method according to claim 1 wherein the individual types of leukocytes are comprised of monocytes and neutrophils, and the distribution zones set in the first two-dimensional plot are the distribution zones of monocytes and neutrophils and, monocytes, intact neutrophils, and neutrophils with damaged cell membranes are separated from one another on the second two-dimensional plot.
3. A method of classifying leukocytes by flow cytometry which comprises the steps of:(a) mixing a sample of blood with a hypotonic first fluid comprising a first dye that is a fluorescent dye capable of selectively staining both eosinophils and basophils, said first dye being Astrazon Yellow 3G, a second dye that is a fluorescent dye capable of staining the nuclei of leukocytes, said second dye selected from the group consisting of: Acridine Red; Rhodamine S; Rhodamine 6G Rhodamine B Rhodamine 19 perchlorate; Rhodamine 123 Eosin Y; Cyanosine; Cresyl Fast Violet; Darrow Red; Acronol Phloxine FFS; 1,1'-dimethylthiocarbocyanine; 1,1'-diethylthiocarbocyanine; 1,1-diethyl-9-methylthiocarbocyanine bromide; 2-[γ-(1'-ethyl-4', 5'-benzothiazolylidene) -propenyl]-1-ethyl-4,5-benzoxazolium iodide; Astrazon Red 6B; Basic Violet 16; 2-(p-dimethylaminostyryl-1-ethyl-4,5 benzo-thiazolium iodide; 2,4-bis(p-dimethylaminostyryl)-1-ethyl-pyridinium iodide; 2,6-bis(p-dimethylaminostyryl)-1-ethyl-pyridinium iodide; and Astrazon Orange R;a third dye that is a fluorescent dye capable of staining the nuclei of leukocytes with damaged cell membrane, said third dye selects from the group consisting of Propidium Iodide Etidium Bromide and M-264, and a buffer for maintaining a pH in an acidic range to obtain first sample solution, incubating said first sample solution; (b) mixing the first sample solution obtained in step (a) with a second fluid comprising a buffer that neutralizes acid in the first fluid for maintaining the pH of the solution at a staining pH and an osmolarity adjusting agent for adjusting the osmolarity of the solution a value at which the leukocytes remain unchanged in shape to obtain a second sample solution, incubating said second sample solution, said dyes cooperating to enable a combined total incubation period of about one minute; (c) loading the second sample solution obtained in step (b) in a flow cytometer and obtaining more than one signal for parameters including fluorescence and scattered light in association with individual types of leukocytes; (d) constructing a first two-dimensional plot of intensities of scattered light and green fluorescence from the signals as emitted from leukocytes, said plot containing distribution zones of each leukocyte type, and counting leukocytes within each zone to obtain a number for undamaged leukocytes of each leukocyte type located in the distribution zones of intact leukocytes; (e) further separating and counting leukocytes within distribution zones of individual leukocyte types on said first two-dimensional plot by determining distribution zones for leukocytes with damaged membranes, (f) constructing, for the leukocytes with damaged membranes in those determined distribution zones for leukocytes with damaged membranes, a second two-dimensional plot of the intensities of scattered light and red fluorescence, (g) separating on said second two-dimensional plot those leukocytes with damaged membrane and counting to obtain a number for damaged leukocytes of each leukocyte type located in the zones of leukocytes with damaged membranes; (h) combining the number of undamaged leukocytes located in the zones of intact leukocytes and the number of damaged leukocytes located in the zones of leukocytes with damaged membranes to obtain a total number of each type of leukocytes in said blood sample. 4. A method of classifying leukocytes by flow cytometry which comprises the steps of:(a) mixing a sample of blood with a hypotonic first fluid comprising a first dye that is a fluorescent dye capable of selectively staining both eosinophils and basophils, said first dye being Astrazon Yellow 3G a second dye that is a fluorescent dye capable of staining the nuclei of leukocytes, said second dye selected from the group consisting of: Acridine Red; Rhodamine S; Rhodamine 6G Rhodamine B Rhodamine 19 perchlorate; Rhodamine 123 Eosin Y; Cyanosine; Cresyl Fast Violet; Darrow Red; Acronol Phloxine FFS; 1,1'-dimethylthiocarbocyanine; 1,1'-diethylthiocarbocyanine; 1,1-diethyl-9-methylthiocarbocyanine bromide; 2-[γ-(1'-ethyl-4', 5'-benzothiazolylidene) -propenyl]-1-ethyl-4,5-benzoxazolium iodide; Astrazon Red 6B; Basic Violet 16; 2-(p-dimethylaminostyryl-1-ethyl-4,5 benzo-thiazolium iodide; 2,4-bis(p-dimethylaminostyryl)-1-ethyl-pyridinium iodide; 2,6-bis(p-dimethylaminostyryl)-1-ethyl-pyridinium iodide; and Astrazon Orange R;a third dye that is a fluorescent dye capable of staining the nuclei of leukocytes with damaged cell membrane, said third dye selected from the group consisting of Propidium Iodide, Etidium Bromide and M-264, and a buffer for maintaining a pH in an acidic range to obtain a first sample solution, incubating said first sample solution; (b) mixing the first sample solution obtained in step (a) with a second fluid comprising a buffer that neutralizes acid in the first fluid for maintaining the pH of the solution at a staining pH and an osmolarity adjusting agent for adjusting the osmolarity of the solution to a value at which the leukocytes remain unchanged in shape to obtain a second sample solution, incubating said second sample solution, said dyes cooperating to enable a combined total incubation period of about one minute; (c) loading the second sample solution obtained in step (b) in a flow cytometer and obtaining more than one signal for parameters including fluorescence and scattered light in association with individual types of leukocytes; (d) constructing a first two-dimensional plot of intensity of scattered light plotted against intensity of green fluorescence from the respective signals as emitted from leukocytes in said flow cytometer, said plot defining distribution zones of each intact leukocyte type, and counting to obtain a number for each leukocyte type located in the distribution zones of intact leukocytes; (e) further separating leukocyte cell groups within each distribution zone, by constructing for each distribution zone a second plot of the intensity of scattered light plotted against intensity of red fluorescence from the respective signals emitted from leukocytes in said flow cytometer, whereby said second plot includes cells having damaged membrane of leukocyte types that would be found in distribution zones for each intact leukocyte type. (f) distinguishing on said second plot said leukocyte cell groups having damaged membranes, and counting to obtain a number for each type of leukocyte having damaged membranes in each distribution zone; and (g) combining the number for each leukocyte type located in the distribution zones of intact leukocytes and the number of for each type of leukocyte having damaged membranes to obtain a total number of each type of leukocytes in said blood sample. 5. A method according to claim 3 wherein the distribution zones set in the first two-dimensional plot are the distribution zones of monocytes and neutrophils and, monocytes, intact neutrophils and neutrophils with damaged cell membrane are separated from one another on the second two-dimensional plot.
6. A method according to claim 4 wherein the distribution zones set in the first two-dimensional plot are the distribution zones of monocytes and neutrophils and, monocytes, intact neutrophils and neutrophils with damaged cell membrane are separated from one another on the second two-dimensional plot.
7. The method as defined in claims 1, 3, or 4, wherein said step of loading the second sample and obtaining signals includes irradiating said second sample with a single wavelength.
8. The method as defined in claim 7, wherein said single wavelength is 488 nm.
9. The method as defined in claims 1 or 3 comprising the additional step preceding step (b) of:incubating said first sample for a period of time equal to less than 1 minute. 10. The method as defined in claim 9, comprising the additional step preceding step (c) of:incubating said second sample for a period of time equal to less than 1 minute. 11. The method as defined in claim 10, wherein said incubation time of said first sample combined with said incubation time of said second sample is less than 1 minute.
This is a continuation of application Ser. No. 07/790,415, filed Nov. 7, 1991, now abandoned.
This invention relates to a method for classifying leukocytes in the practice of clinical testing. More particularly, this invention relates to a method of classifying leukocytes with a flow cytometer by means of optical measurements on blood cells stained with fluorescent dyes, which method is capable of maintaining the desired precision of leukocyte classification irrespective of the difference in the lapse of time following blood sampling.
Leukocytes in the peripheral blood of normal subjects can be classified as being of five types consisting of lymphocytes, monocytes, neutrophils, eosinophils, and basophils. Different leukocyte types have different functions and counting of leukocytes in the blood according to their type provides valuable information for diagnostic purposes. For instance, an increase in the number of neutrophils is-associated with inflammation, and diseases such as myocardial infarction and leukemia, and a decrease in their number is associated with vital diseases, hypoplastic anemia, agranulocytosis, etc. On the other hand, an increase in the number of eosinophils is found in such diseases as parasitosis, Hodgkin's disease and allergosis. An increased number of monocytes occurs either during the convalescence period of patients suffering from infectious diseases or in such diseases as monocytic leukemia.
Classification and counting of leukocytes have been made most commonly by the differential counting method which is also referred to as the visual counting method or simply as the manual method. In this method, a blood sample is smeared on a glass slide and the blood corpuscles in the smear are fixed and stained for examination by microscopy. The technician identifies the type of individual leukocytes according to their morphological features (e.g., their size, the morphology of their nucleus and cytoplasm, and the presence or absence of granules) or the degree of dye uptake and performs classification and counting of them. In ordinary laboratories, 100-200 leukocytes are usually counted for each sample and the percentage of the total leukocyte count occupied by each type of corpuscle is recorded as a measured value.
Techniques that fall within the category of this flow cytometric method are described in, for example, Japanese Patent Publication No. 853/1984 and L. A. Kamentsky, Blood Cells, 6, 121-140 (1980). According to these techniques, a blood sample is stained with 10 volumes of an Acridine Orange solution, incubated for 1 minute, and irradiated under a light source such as an argon ion laser. The green fluorescence and red fluorescence that are emitted from the individual corpuscles are measured and classification and counting of leukocytes are subsequently made based on a two-dimensional plot of the fluorescence measurements.
The flow cytometer employed in these methods uses either a mercury lamp that produces three different wavelengths of light or three lasers, so as to excite the three fluorescent stains in each of the dye solutions. The parameters measured are three kinds of fluorescence, forward scattered light, side-scattered light and absorbed light. Based on these six parameters, two-dimensional plots are constructed in four stages and analyzed to make leukocyte classification and counting.
Unexamined Published Japanese Patent Application No. 70166/1988 discloses a one-step staining process consisting of staining a blood sample with a dye solution comprised of a buffer solution, inorganic salts and fluorescent dyes. But this method has the problem that unlysed erythrocytes may adversely affect measurement data to produce unreliable results.
Unexamined Published Japanese Patent Application No. 134958/1988 discloses a two-step staining process that uses a hypotonic acidic fluorescent dye solution and a solution that will changes its osmolarity and pH. A blood sample stained with those solutions is loaded in a flow cytometer to obtain signals for fluorescence and side-scattered light and on the basis of those signals, a two-dimensional plot of fluorescence intensity vs the intensity of side-scattered light is constructed as shown in FIG. 2, whereby the leukocytes in the sample are classified into five types. Numerals 1-6 in FIG. 2 signify the populations of lymphocytes, monocytes, neutrophils, eosinophils, basophils and a noise component, respectively.
In the first version of the method that uses a flow system for leukocyte classification and counting, the disruption of erythrocytes is a prerequisite but depending on blood sample, it is impossible to effect complete lysis of erythrocytes and the accuracy of measurements may be impaired in such a case.
The examples of the flow cytometric approach that are described in Japanese Patent Publication No. 853/1984 and Blood Cells, 6, 121-140 (1980) are characterized by performing measurements before dye absorption by the cells reaches an equilibrium, or at the time when the difference between the intensities of fluorescence from individual leukocytes attains a maximum during the staining process. However, the time required for attaining an appropriate level of fluorescence intensity in a sample whose leukocyte count is at either one of two extremes will be different from the time for a normal sample and an appropriate staining time must be selected for each sample. As a further problem, this method relies solely on the differential intensity of fluorescence for leukocyte classification and does not necessarily ensure precise separation between different leukocyte types such as lymphocytes and monocytes.
The other examples of the cytometric approach that are described in Unexamined Published Japanese Patent Application No. 20820/1975, J. Histochem, Cytochem., 24 (1) 396-411 (1976) and supra, 25 (8) 976-989 (1977) have the disadvantage that they involve many steps of operation and staining takes a prolonged time and requires the use of reagents in a complex system. Furthermore, practice of these methods requires a very sophisticated and costly apparatus that includes three light sources and which is capable of measuring six parameters. In addition, analysis of such a large number of parameters is inevitably complicated and requires an analyzer having a large capacity.
All of the prior art techniques of flow cytometric approach including the method proposed by Unexamined Published Japanese Patent Application No. 70166/1988 have one common problem in that detection with a flow cytometer is impossible if neutrophils in a blood sample die when a long time passes before measurement. The method described in Unexamined Published Japanese Patent Application No. 134958/1988 aims at detecting dead cells to obtain correct neutrophil counts but, depending on the specimen to be assayed, it is sometimes impossible to achieve complete differentiation of dead cells. The problem also occurs in the case of damaged cells because the zone of their distribution becomes mixed up with the distribution zone of intact cells or another cell type, thereby making it impossible to perform complete differentiation between the two cell groups. In order to avoid these problems, measurements by the conventional flow cytometric methods always require the use of fresh blood samples.
The present invention has been accomplished under these circumstances and has as an object providing a method capable of more correct classification of leukocytes regardless of the difference between specimens and the presence of cells which, on account of damaged cell membrane or other reasons, are distributed in positions that are different from those which would otherwise occur in a normal situation. The method enables accurate classification and counting of leukocytes by simple procedures.
The method of the present invention for leukocyte classification relies basically upon flow cytometry that uses a first fluid that is hypotonic acidic fluorescent dye solution and a second fluid that is a solution that changes the osmolarity and pH of the first fluid. In accordance with the present invention, a fluorescent dye that specifically stains the nuclei of damaged leukocyte cells is added to the first fluid and the resulting fluid is used in measurements. By analysis conducted on the basis of the resulting two kinds of two-dimensional plot, with them being correlated to each other, the number of leukocyte cells which, on account of a damaged cell membrane or for other reasons, are distributed in positions that are different from those which would otherwise occur in the normal situation, is determined to obtain the final results of leukocyte classification.
Stated more specifically, a third dye such as PI (Propidium iodide) or EB (Ethidium bromide) is added to the first fluid and two kinds of two-dimensional plot, one plotting the intensity of red-fluorescence against the intensity of side-scattered light and the other plotting the intensity of green fluorescence against the intensity of side-scattered light, are analyzed with them being correlated to each other, whereby the number of denatured leukocyte cells, such as neutrophils with damaged cell membranes, that have come to be distributed in different positions than would otherwise be the case in a normal situation on account of such factors as the lapse of a prolonged time after blood sampling can be determined.
First dye: Astrazon Yellow 3G
Second dye: Acridine Red;
2-[γ-(1'-ethyl-4',5'-benzothiazolylidene)-propenyl]-1-ethyl-4,5-benzoxazolium iodide;
2-(p-dimethylamlnostyryl)-1-ethyl-4,5-benzothiazolium iodide;
Third dye: Propidium iodide;
FIG. 2 is a two-dimensional plot for the intensity of green fluorescence vs the intensity of side-scattered light, as obtained in measurement of a fresh blood sample (within 6 h after sampling) using a prior art reagent, i.e., the first fluid in the absence of the third dye;
FIG. 3 is a two-dimensional plot for the intensity of green fluorescence vs the intensity of side-scattered light, as obtained in the same measurement except that the blood sample was left at room temperature for a prolonged period, say for 20 h;
FIG. 4 is a first type of two-dimensional plot for the intensity of green fluorescence vs the intensity of side-scattered light;
FIG. 5 is a second type of two-dimensional plot for the intensity of red fluorescence vs the intensity of side-scattered light;
FIG. 6 is a two-dimensional plot obtained by fractionating the first type of two-dimensional plot shown in FIG. 4;
FIG. 7 is a second type of two-dimensional plot as constructed for the three cell types within zone II of FIG. 6;
FIG. 8 is a graph showing the time-dependent profiles of the relative counts of five leukocyte types as obtained by performing analysis with the first and second fluids used in the example to be described below;
FIG. 9 is a graph showing the results of leukocyte classification that was performed with the prior art first fluid, followed by analysis on the basis of a two-dimensional plot of the intensity of green fluorescence vs the intensity of side-scattered light;
FIG. 10 is a two-dimensional plot of the intensity of green fluorescence vs the intensity of side-scattered light;
FIG. 11 is a two-dimensional plot of-the intensity of red fluorescence vs the intensity of side-scattered light;
FIG. 12 is another two-dimensional plot of the intensity of green fluorescence vs the intensity of side-scattered light; and
FIG. 13 is another two-dimensional plot of the intensity of red fluorescence vs the intensity of side-scattered light.
Basic Yellow 11 and Astrazon Orange R are commercial products that are available from Aldrich Chemical Company, Inc. and Tokyo Kasei K.K., respectively.
If the concentration of Basic Yellow 11 is above a certain level, the intensity of fluorescence from basophils is higher than that from .the other types of leukocytes, and the intensity of fluorescence from eosinophils also increases at higher concentrations. The intensities of fluorescence from lymphocytes, neutrophils and monocytes are virtually independent of the concentration of Basic Yellow 11. Hence, in order to differentiate basophils and eosinophils from the other types of leukocytes in terms of the intensity of fluorescence, the concentration of Basic Yellow 11 may be adjusted to 70-100 ppm and higher.
Etidium bromide is a commercial product available from Nacalai Tesque, Inc. If the concentration of Etidium bromide is 3 ppm (3 μg/ml) and below, the appearance of damaged cells in a two-dimensional plot is not consistent (they appear in variable positions). Above 100 ppm, the S/N ratio of signal detection decreases (the difference between a fluorescence signal and the background becomes so small as to prevent effective signal detection). The same discussion may apply to the concentration of Propidium iodide.
In order to lyse erythrocytes, the pit of the first fluid is preferably set at 5.0 and below but in order to prevent coagulation of platelets, the pit of the first fluid must be at least 3.5.
In accordance with the present invention, not only a fluorescence signal but also a side-scattered light signal is produced from leukocytes. The fluorescence signal reflects the cytochemical characters of leukocytes and depending on the interaction between stains and individual leukocyte types, signals of different intensities are produced from the leukocytes. The right-angle scattering light signal reflects the structural information of an individual white cell. The larger the nucleus of a white blood cell and the more granules that are present in it, the greater the light reflection which will occur in the cell to produce a more intense side-scattered light. A lymphocyte contains very few or no granules, so the scattered light produced from the lymphocyte is the weakest of all leukocytes. On the other hand, a neutrophil contains many granules and has a large nucleus, so it produces a more intense scattered light. Eosinophils produce scattered light the intensity of which is comparable to that produced from neutrophils. Monocytes and basophils produce scattered light having an intensity intermediate between those of scattered light from lymphocytes and neutrophils.
A specific example of the optics of a flow cytometer employed in the present invention is hereunder described with reference FIG. 1. The optics shown in FIG. 1 is used in a flow cytometer designed for measuring side-scattered light, red fluorescence and green fluorescence. The optics generally indicated by 10 uses an argon ion laser 12 as a light source and it operates at a wavelength of 488 rim, producing an output of 10 mW. Light emitted from the laser 12 is converged by a cylindrical lens 16 and illuminates a blood sample flowing through a flow cell 14.
When the stained leukocytes in the sample are irradiated by the laser light, they produce scattered light and fluorescence. The side scattered light and the fluorescence are converged with a condenser lens 18 and pass through an aperture 20 to fall upon a dichroic mirror 22. The dichroic mirror 22 reflects the side scattered light 24 and transmits the fluorescence 26. The side scattered light 24 reflected from the dichroic mirror 22 is detected in a photomultiplier tube 28. Of the two kinds of fluorescence 26 that passes through the dichroic mirror 22, red fluorescence 32 is reflected by a dichroic mirror 30 and green fluorescence 38 is transmitted through that mirror. The reflected red fluorescence 32 passes through a color filter 34 and is detected in a photomultiplier tube 36. The transmitted green fluorescence 38 passes through a color filter 40 and is detected in a photomultiplier tube 42.
Erythrocytes in the blood sample emit only fluorescence of very low intensity, so if all that is needed is to measure the intensity of fluorescence, erythrocytes will not interfere with the counting of leukocytes even if coincidence of erythrocytes and leukocytes occurs (i.e., erythrocytes and leukocytes pass through the detecting portion simultaneously). However, if one wants to measure the scattered light, erythrocytes which produce scattered light having an intensity comparable to that of the scattered light emitted from leukocytes will interfere with the counting of leukocytes. In this case, one may measure fluorescence and scattered light simultaneously and regard as leukocytes only the corpuscles that emit fluorescence having an intensity greater than a certain level. However, if coincidence of leukocytes and erythrocytes occurs, the scattered light from erythrocytes is superposed on the scattered light from leukocytes, thereby making accurate measurement of scattered light from the leukocytes impossible. In the optics 10 of a flow cytometer shown in FIG. 1, a blood sample is permitted to flow through the flow cell 14 after it has been diluted by, for example, 20 fold so that the probability of coincidence of erythrocytes and leukocytes is reduced and the potential interference by erythrocytes is decreased to a level that can be disregarded for practical purposes.
Specifically, the method of the present invention is an improvement of the invention described in Unexamined Published Japanese Patent Application No. 282698/1988 (Example 2, 2: 2-step method) and it is illustrated below with reference to a working example. It should, however, be noted that the following example is in no way intended to limit the present invention.
Two reagents were prepared to the formulas indicated below. The first dye in the first fluid was a fluorescent dye that would selectively stain both eosinophils and basophils; the second dye in the first fluid was a fluorescent dye that would stain the nuclei of leukocytes; and the third dye in the first fluid was a fluorescent dye that would stain the nuclei of leukocytes that were damaged in a cell membrane.
______________________________________First fluid______________________________________First dye    Basic Yellow 11 (Aldrich)                      100      ppmSecond dye    Astrazon Orange R (Tokyo                      330      ppm    Kasei)Buffer   Diglycolic acid-sodium                      10       mM    hydroxideThird dye    Etidium bromide   5.5      ppm(preferably 3-100           ppm)pH, 4.0; osmolarity, 30 mOsm/kg______________________________________
In the first fluid, EB (Etidium bromide) would bind to a G-C pair in DNA by intercalation and so would PI (Propidium iodide).
______________________________________Second fluid______________________________________Buffer       Tricin-sodium hydroxide                        300 mMOsmolarity   Sodium chloride 750 mMadjustingagentpH, 9.8-9.9; osmolarity, 2200 mOsm/kg______________________________________
First, the blood of a healthy person was made nonclotting and 100 μl of the thus anti-coagulated blood was mixed uniformly with 1800 μl of the first fluid. After agitation, the mixture was incubated at 25� C. for ca. 20 seconds. Thereafter, 200 μl of the second fluid was added and the mixture was agitated, followed by incubation at 25� C. for ca. 40 seconds. The finally obtained sample solution had a pit of 8.6-8.7 and an osmolarity of ca. 280 mOsm/kg (isotonic).
The results of measurements are described below with reference to the accompanying FIGS. 2-13.
FIG. 2 is a two-dimensional plot of the intensity of green fluorescence vs the intensity of side-scattered light as obtained when measurements were conducted using the prior art reagent, namely the first fluid not containing the third dye. Numerals 1-6 in the plot signify the distribution zones of lymphocytes, monocytes, neutrophils, eosinophils, basophils and erythrocyte ghost, respectively. (A two-dimensional plot of the intensity of red fluorescence vs the intensity of side-scattered light was found to show the same pattern of distribution.) By separating each distribution zone and counting the number of particles in it, the count of leukocytes of a specific type can be obtained. By repeating this procedure, the proportions of different types of leukocytes can be determined.
The two-dimensional plot of FIG. 2 shows the results of measurements on fresh blood that was not left to stand for more than 6 hours after sampling. If sampled blood is left at room temperature for a prolonged time, say 20 hours, before measurement, the cell membranes of leukocytes are damaged and some of them will be distributed in a different zone than the cells of interest would otherwise be located. If the distribution of such cells is within the zone of another type of cells, the precision of leukocyte classification will decrease. The effect of overlap between two distribution zones is the greatest if, as shown in FIG. 3, some part of the neutrophil population is distributed in the zone of monocytes. When the conventional reagent was used, the two kinds of two-dimensional plot (one for plotting the intensity of green fluorescence vs the intensity of side-scattered light and the other for plotting the intensity of red fluorescence vs the intensity of side-scattered light). Hence, in the conventional practice, a certain zone is set in each two-dimensional plot as an area where substantially no leukocytes are distributed if the blood is fresh but where a measurable number of leukocytes appear if the blood is left to stand for a prolonged time, and the cells falling in that zone have been regarded as dead neutrophil cells.
However, this approach has not always assured satisfactory precision on account of various factors such as variations among specimens and the difference in the degree of cell damage.
Under these circumstances, the method of the present invention modifies the conventional reagent and uses the first fluid incorporating the third dye and this has proved to be very effective in maintaining the precision of leukocyte classification at high level. Etidium bromide used in the example under consideration is known as a substance that stains dead cells. However, when measurements were conducted using a fluid that did not contain the first or second dye but which contained Etidium bromide as the sole dye (the other conditions of preparation were the same as described above), damaged cells could not be detected even from blood samples that contained many damaged leukocyte cells. This fact is clear from FIGS. 12 and 13. FIG. 12 is a two-dimensional plot of the intensity of green fluorescence vs the intensity of side-scattered light, and FIG. 13 is a two-dimensional plot of the intensity of red fluorescence vs the intensity of side-scattered light. Obviously, damaged leukocyte cells were not detectable in either case.
When measurements were conducted on the same specimens using the first fluid under consideration which incorporated not only the third dye but also the first and second dyes, damaged leukocyte cells could be detected as distinct entities from the intact cells. FIGS. 10 and 11 are two-dimensional plots; the graph of FIG. 10 plots the intensity of green fluorescence vs the intensity of side-scattered light and the graph of FIG. 11 plots the intensity of red fluorescence vs the intensity of side-scattered light. The damaged leukocyte cells are shown in FIG. 11 as enclosed with a circle. In short, it is of great importance to incorporate not only the first and second dyes but also the third dye in the reagent for leukocyte classification and the present invention has been accomplished on the basis of the finding of this important fact.
The distribution zones of various leukocyte types that can be obtained by the method of the present invention using the first fluid described above are discussed more specifically below.
FIG. 5 is a second two-dimensional plot of the intensity of red fluorescence vs the intensity of side-scattered light. Numerals 1-8 in the plot signify the zones of lymphocytes, monocytes, neutrophils, eosinophils, basophils, erythrocyte ghost, neutrophils with damaged cell membrane, and lymphocytes with damaged cell membrane, respectively. FIG. 4 is a first two-dimensional plot of the intensity of green fluorescence vs the intensity of side-scattered light. The distribution pattern appearing in FIG. 4 is substantially the same as that obtained using the conventional first fluid; the zone of lymphocytes 8 with damaged cell membrane is within the zone of intact lymphocytes 1 whereas the zone of neutrophils 7 with damaged cell membrane is within the zone of monocytes 2. It should also be noted that the first two-dimensional plot (FIG. 4) has a different distribution pattern from the second two-dimensional plot (FIG. 5). Precise leukocyte classification can be accomplished by performing analysis with the two plots being correlated to each other.
The specific method of data analysis is described below. Those distribution zones in the first two-dimensional plot which are clearly distinguished from one another are separated as such. As for the zones that are not clearly discernible from others, the second two-dimensional plot is constructed to perform more precise separation.
To begin with, the first two-dimensional plot (FIG. 4) is fractionated as shown in FIG. 6; zone I covers both intact lymphocytes 1 and damaged lymphocytes 8; zone II covers monocytes 2, intact neutrophils 3 and damaged neutrophils 7; zone III covers eosinophils 4; and zone IV covers basophils 5.
In the next step, the second two-dimensional plot (see FIG. 7) is constructed for the three types of cells in zone II that are not clearly distinguishable from one another. Those three types of cells do not provide distinct distributions in the first two-dimensional plot but they do provide distinct distributions in the second two-dimensional plot. This is why the three types of cells in zone II are subjected to further separation as shown in FIG. 7, in which zone V covers monocytes 2, zone VI covers intact neutrophils 3, and zone VII covers damaged neutrophils 7. Combining the cells in zones VI and VII, the total count of neutrophils is obtained.
Thus, the counts of all leukocyte types of interest can be determined with high precision.
The consistency of leukocyte classification by the method of the present invention is described below.
FIG. 8 is a graph showing the time-dependent profiles of the relative counts of five leukocyte types as obtained by performing analysis with the first and second fluids used in the example under discussion. The horizontal axis plots the time (in hours) for which blood was left to stand at room temperature after sampling. The symbols in the graph have the following meanings: □, neutrophils; +, lymphocytes; , monocytes; .increment., eosinophils; and �, basophils.
As FIG. 8 shows, the proportions of the five leukocyte counts remained stable for more than 20 hours after sampling.
FIG. 9 is a graph showing the results of leukocyte classification that was performed with the prior art first fluid, followed by analysis on the basis of the resulting two-dimensional plot of the intensity of green fluorescence vs the intensity of side-scattered light. Obviously, the proportion of neutrophils started to decrease and that of monocytes started to increase with the lapse of ca. 8 h after sampling.
In the example under discussion, Etidium bromide was used as the third dye but Propidium iodide and M-264 can also be used with equal effectiveness.
The first fluid to be used in the method of the present invention incorporates not only the first and second dyes but also the third dye and this insures that even leukocytes with a damaged cell membrane can be distributed as entities distinct from other leukocyte types on a two-dimensional plot. Hence, such damaged leukocyte cells can be detected in a consistent manner irrespective of the differences between specimens and those in the degree of cell damage. In accordance with the present invention, final results of measurements are produced by analyzing the detected data and, hence, high precision of leukocyte classification is assured even in the case of assaying blood that contains damaged cells as a result of prolonged standing at room temperature after sampling.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4027971 *Oct 30, 1975Jun 7, 1977Philip KolmanMethod of simultaneously counting blood cellsUS4345027 *Dec 12, 1980Aug 17, 1982The United States Of America As Represented By The United States Department Of EnergyFluorometric method of quantitative cell mutagenesisUS4628026 *Nov 15, 1983Dec 9, 1986Dietlind GardellMethod and apparatus for automated double fluorochromization analysis in lymphocytotoxicity testingUS4637986 *Aug 22, 1983Jan 20, 1987Ortho Diagnostic Systems, Inc.Flow cytometry lysing reagent with leukoprotective agent for producing a 3-part WBC countUS4656139 *Jun 30, 1986Apr 7, 1987Toa Medical Electronics Co., Ltd.Method for preparing cells for blood analysisUS4727020 *Feb 25, 1985Feb 23, 1988Becton, Dickinson And CompanyMethod for analysis of subpopulations of blood cellsUS4751179 *May 31, 1984Jun 14, 1988Coulter Electronics, Inc.Method and reagents for differential determination of four populations of leukocytes in bloodUS4812394 *Feb 24, 1986Mar 14, 1989University Of CaliforniaFlow cytomeric measurement of DNA and incorporated nucleoside analogsUS4902613 *Dec 8, 1986Feb 20, 1990Becton, Dickinson And CompanyLysing agent for analysis of peripheral blood cellsUS4959301 *Apr 22, 1988Sep 25, 1990Massachusetts Institute Of TechnologyProcess for rapidly enumerating viable entitiesUS4968629 *Dec 16, 1987Nov 6, 1990Hematology Marketing Associates, Inc.Blood diluent for automatic and semi-automatic determination of white cells and method of utilizing sameUS4978624 *Sep 14, 1988Dec 18, 1990Technicon Instruments CorporationReagent for the determination of a differential white blood cell countUS5039613 *Sep 1, 1987Aug 13, 1991Toa Medical Electronics Co., Ltd.Reagents used in a method of classifying leukocytes by flow cytometryUS5057413 *Jun 13, 1988Oct 15, 1991Becton, Dickinson And CompanyMethod for discriminating between intact and damaged cells in a sampleUS5084378 *Nov 30, 1987Jan 28, 1992The United States Of America As Represented By The United States Department Of EnergyEnhanced detection of fluorescence quenching in labeled cellsUS5175109 *Feb 28, 1991Dec 29, 1992Toa Medical Electronics Co., Ltd.Reagent for classifying leukocytes by flow cytometry* Cited by examinerNon-Patent CitationsReference1 *Floy J. Green, The Sigma Aldrich Handbook of Stains, Dyes and indicators, 1990, p. 318 and Transmisasion Spectrum Reference chart.2Floy J. Green, The Sigma-Aldrich Handbook of Stains, Dyes and indicators, 1990, p. 318 and Transmisasion Spectrum Reference chart.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5496734 *Jun 2, 1995Mar 5, 1996Toa Medical Electronics Co., Ltd.Treatment method for blood analysisUS5691204 *Apr 21, 1995Nov 25, 1997Abbott LaboratoriesCompositions and methods for the rapid analysis of reticulocytesUS6813017Oct 19, 2000Nov 2, 2004Becton, Dickinson And CompanyApparatus and method employing incoherent light emitting semiconductor devices as particle detection light sources in a flow cytometerUS7488574Mar 17, 2005Feb 10, 2009Sysmex CorporationApparatus and method for cell analysisUS7491502Dec 17, 2004Feb 17, 2009The General Hospital CorporationIn vivo flow cytometry system and methodUS7740641Sep 15, 2005Jun 22, 2010Ethicon Endo-Surgery, Inc.Clip applier with migrational resistance featuresUS8038686Sep 15, 2005Oct 18, 2011Ethicon Endo-Surgery, Inc.Clip applier configured to prevent clip falloutUS8075571Oct 9, 2007Dec 13, 2011Ethicon Endo-Surgery, Inc.Surgical clip applier methodsUS8108031Aug 27, 2007Jan 31, 2012The General Hospital CorporationMethods for in-vivo flow cytometryUS8178342Jan 7, 2009May 15, 2012The General Hospital CorporationIn vivo flow cytometry system and methodUS8211660May 24, 2010Jul 3, 2012The General Hospital CorporationIn-vivo monitoring of circulating apoptotic cellsUS8216257May 19, 2011Jul 10, 2012Ethicon Endo-Surgery, Inc.Clip applier configured to prevent clip falloutUS8236012Jul 23, 2007Aug 7, 2012Ethicon Endo-Surgery, Inc.Surgical clip advancement mechanismUS8241238 *May 15, 2007Aug 14, 2012Hamamatsu Photonics K.K.Cell selection apparatusUS8246634Mar 29, 2010Aug 21, 2012Ethicon Endo-Surgery, Inc.Surgical clip applier ratchet mechanismUS8246635Jun 11, 2010Aug 21, 2012Ethicon Endo-Surgery, Inc.Clip applier with migrational resistance featuresUS8262679Oct 9, 2009Sep 11, 2012Ethicon Endo-Surgery, Inc.Clip advancerUS8267945Dec 1, 2009Sep 18, 2012Ethicon Endo-Surgery, Inc.Clip advancer with lockout mechanismUS8328822May 19, 2011Dec 11, 2012Ethicon Endo-Surgery, Inc.Surgical clip applier ratchet mechanismUS8496673May 19, 2011Jul 30, 2013Ethicon Endo-Surgery, Inc.Clip advancer with lockout mechanismUS8523882Sep 15, 2005Sep 3, 2013Ethicon Endo-Surgery, Inc.Clip advancer mechanism with alignment featuresUS8574859Mar 27, 2009Nov 5, 2013The General Hospital CorporationIn vivo flow cytometry based on cellular autofluorescenceUS8753356Oct 9, 2007Jun 17, 2014Ethicon Endo-Surgery, Inc.Surgical clip applier methodsUS8821516May 19, 2011Sep 2, 2014Ethicon Endo-Surgery, Inc.Clip applier with migrational resistance featuresUS8915930Sep 14, 2007Dec 23, 2014Ethicon Endo-Surgery, Inc.Force limiting mechanism for medical instrumentCN101454437BMay 15, 2007Jun 27, 2012国立大学法人浜松医科大学Cell selection apparatusEP1785720A2 *Nov 13, 2006May 16, 2007Sysmex CorporationBlood analyzer and blood analyzing methodWO2001029538A1 *Oct 19, 2000Apr 26, 2001Becton Dickinson CoAn apparatus and method employing incoherent light emitting semiconductor devices as particle detection light sources in a flow cytometer* Cited by examinerClassifications U.S. Classification436/17, 436/174, 436/172, 436/166, 436/805, 436/800International ClassificationG01N33/48, G01N33/49, G01N15/00, G01N15/14Cooperative ClassificationY10T436/25, Y10T436/107497, Y10S436/805, Y10S436/80, G01N15/1456, G01N2015/008, G01N2021/6441European ClassificationG01N15/14GLegal EventsDateCodeEventDescriptionApr 16, 1996CCCertificate of correctionFeb 9, 1999REMIMaintenance fee reminder mailedJul 18, 1999LAPSLapse for failure to pay maintenance feesSep 28, 1999FPExpired due to failure to pay maintenance feeEffective date: 19990718RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services